Drugs for Myotonic Dystrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 42)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Methylphenidate |
Approved, Investigational |
Phase 2, Phase 3 |
|
113-45-1 |
4158 |
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
298-59-9 (hydrochloride)
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
4311/B Ciba
AC1L1HJM
alpha-Phenyl-2-piperidineacetate methyl ester
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
a-Phenyl-2-piperidineacetate methyl ester
a-Phenyl-2-piperidineacetic acid methyl ester
C 4311
C07196
Calocain
Celltech brand OF methylphenidate hydrochloride
Centedein
Centedrin
Centedrine
Centredin
Cephalon brand OF methylphenidate hydrochloride
CHEBI:6887
CHEMBL796
CID4158
Concerta
D04999
Daytrana
Daytrana (TN)
DB00422
DB06701
DEA No. 1724
d-methylphenidate HCl
D-Methylphenidate HCL
EINECS 204-028-6
Equasym
Focalin
Focalin XR
HSDB 3126
Hydrochloride, methylphenidate
L001307
LS-565
Mallinckrodt brand OF methylphenidate hydrochloride
Meridil
Metadate
Metadate CD
Metadate ER
Methyl (2-phenyl-2-(2-piperidyl)acetate)
methyl 2-phenyl-2-piperidin-2-ylacetate
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-(2-piperidyl)acetic acid
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl alpha-phenyl-alpha-2-piperidinylacetic acid
Methyl a-phenyl-a-(2-piperidyl)acetate
Methyl a-phenyl-a-(2-piperidyl)acetic acid
Methyl a-phenyl-a-2-piperidinylacetate
Methyl a-phenyl-a-2-piperidinylacetic acid
Methyl phenidate
|
Methyl phenidyl acetate
Methyl phenidylacetate
Methyl phenidylacetic acid
methyl phenyl(piperidin-2-yl)acetate
methyl α-phenyl-α-(2-piperidyl)acetate
Methyl α-phenyl-α-(2-piperidyl)acetate
Methyl α-phenyl-α-(2-piperidyl)acetic acid
methyl α-phenyl-α-2-piperidinylacetate
Methyl α-phenyl-α-2-piperidinylacetate
Methyl α-phenyl-α-2-piperidinylacetic acid
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
methylphenidate
Methylphenidate
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
Methylphenidate (USAN/INN)
Methylphenidate [INN:BAN]
Methylphenidate HCl
Methylphenidate HCL
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidic acid
Methylphenidylacetate hydrochloride
Methypatch
MethyPatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
MPH
nchembio.2007.55-comp28
NCI-C56280
Novartis brand 1 OF methylphenidate hydrochloride
Novartis brand 2 OF methylphenidate hydrochloride
Phenidylate
Plimasine
PMS-Methylphenidate
Riphenidate
Ritalin
Ritalin hydrochloride
Ritalin LA
Ritalin SR
Ritaline
Ritalin-SR
Ritcher works
Ritcher Works
Tsentedrin
UNII-207ZZ9QZ49
α-phenyl-2-piperidineacetate methyl ester
α-phenyl-2-piperidineacetic acid methyl ester
|
|
2 |
|
Dopamine |
Approved |
Phase 2, Phase 3 |
|
51-61-6, 62-31-7 |
681 |
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
3 |
|
Lamotrigine |
Approved, Investigational |
Phase 3 |
|
84057-84-1 |
3878 |
Synonyms:
3,5-diamino-6-(2,3-dichlorophenyl)- as -triazine
3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
3,5-diamino-6-(2,3-Dichlorophenyl)-1,2,4-triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
3,5-diamino-6-(2,3-Dichlorophenyl)-as-triazine
3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine
6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine
6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diyldiamine
84057-84-1
AC-10298
AC1L1GWT
BIDD:GT0794
Bio-0056
BW 430C
BW-430C
C047781
CHEBI:138727
CHEBI:6367
CHEMBL741
CID3878
CPD000058464
Crisomet
D00354
DB00555
Desitin Brand of Lamotrigine
EINECS 281-901-8
EU-0100688
EUR-1048
Faes Brand of Lamotrigine
GI 267119X
Glaxo Wellcome Brand of Lamotrigine
GlaxoSmithKline Brand of Lamotrigine
GW 273293
HMS2051C10
HMS2089M08
HMS2093P21
HSDB 7526
Juste Brand of Lamotrigine
L 3791
L3791_SIGMA
|
Labileno
Lamictal
Lamictal (TN)
Lamictal Cd
Lamictal CD
Lamictal ODT
Lamictal XR
Lamictin
Lamiktal
Lamitor
Lamotrigina
Lamotrigina [Spanish]
lamotrigine
Lamotrigine
Lamotrigine (JAN/USAN/INN)
Lamotrigine [USAN:INN:BAN]
Lamotriginum
Lamotriginum [Latin]
Lopac0_000688
Lopac-L-3791
LS-155249
MLS000069685
MLS000759486
MLS001077325
MolPort-003-666-744
NCGC00015605-01
NCGC00015605-02
NCGC00015605-06
NCGC00015605-08
NCGC00022936-02
NCGC00022936-04
NCGC00022936-05
NSC746307
SAM001246697
SMP2_000303
SMR000058464
STK628377
Tocris-1611
UNII-U3H27498KS
ZINC00013156
|
|
4 |
|
Dehydroepiandrosterone |
Approved, Investigational, Nutraceutical |
Phase 2, Phase 3 |
|
53-43-0 |
9860744 |
Synonyms:
(+)-Dehydroisoandrosterone
(3beta)-3-Hydroxy-androst-5-en-17-one
(3-beta)-3-Hydroxyandrost-5-en-17-one
(3beta,16alpha)-3,16-Dihydroxy-androst-5-en-17-one
17-Chetovis
17-Hormoforin
3-beta-hydroxy-5-androsten-17-one
3beta-Hydroxy-5-androsten-17-one
3-beta-Hydroxy-5-androsten-17-one
3beta-hydroxyandrost-5-en-17-one
3beta-Hydroxyandrost-5-en-17-one
3beta-Hydroxy-androst-5-en-17-one
3-beta-Hydroxyandrost-5-en-17-one
3beta-Hydroxy-D5-androsten-17-one
3b-Hydroxyandrost-5-en-17-one
3b-Hydroxy-D5-androsten-17-one
3β-hydroxyandrost-5-en-17-one
5,6-Dehydroisoandrosterone
5,6-Didehydroisoandrosterone
5-Androsten-3beta-ol-17-one
5-Androsten-3-beta-ol-17-one
5-Androsten-3b-ol-17-one
5-dehydro-Epiandrosterone
5-Dehydroepiandrosterone
|
Andrestenol
Androst-5-ene-3beta-ol-17-one
Androst-5-ene-3b-ol-17-one
Androsten-3beta-ol-17-one
Androstenolone
Astenile
D5-Androsten-3beta-ol-17-one
D5-Androsten-3b-ol-17-one
Deandros
Dehydroandrosterone
dehydro-Epi-androsterone
Dehydroepiandrosterone
Dehydroisoandrosterone
DHEA
Diandron
Diandrone
Hydroxyandrostenone
Prasterona
Prasterone
Prasteronum
Prestara
Psicosterone
trans-Dehydroandrosterone
|
|
5 |
|
Dopamine Agents |
|
Phase 2, Phase 3 |
|
|
|
6 |
|
Neurotransmitter Agents |
|
Phase 2, Phase 3 |
|
|
|
7 |
|
Sodium Channel Blockers |
|
Phase 3 |
|
|
|
8 |
|
Diuretics, Potassium Sparing |
|
Phase 3 |
|
|
|
9 |
|
Hormones |
|
Phase 3 |
|
|
|
10 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
11 |
|
Antipsychotic Agents |
|
Phase 3 |
|
|
|
12 |
|
Anticonvulsants |
|
Phase 3 |
|
|
|
13 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
14 |
|
calcium channel blockers |
|
Phase 3 |
|
|
|
15 |
|
Adjuvants, Immunologic |
|
Phase 2, Phase 3 |
|
|
|
16 |
|
DHEA (Dehydroepiandrosterone) |
|
Phase 2, Phase 3 |
|
|
|
17 |
|
Immunologic Factors |
|
Phase 2, Phase 3 |
|
|
|
18 |
|
Calcium |
Nutraceutical |
Phase 3 |
|
7440-70-2 |
271 |
Synonyms:
Blood coagulation factor XIII
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
CALCIUM ion
Calcium, doubly charged positive ion
Calcium, elemental
Coagulation factor XIII
Elemental calcium
Factor XIII
|
Factor XIII a chain
Factor XIII a-chain
Factor XIII transamidase
Factor XIII, coagulation
Fibrin stabilizing factor
Fibrinase
Kalzium
Laki lorand factor
Laki-lorand factor
Stabilizing factor, fibrin
Transamidase, factor XIII
XIII, coagulation factor
|
|
19 |
|
Mexiletine |
Approved, Investigational |
Phase 2 |
|
31828-71-4 |
4178 |
Synonyms:
(+-)-1-(2,6-dimethylphenoxy)propan-2-amine
(+-)-1-(2,6-Dimethylphenoxy)propan-2-amine
(±)-1-(2,6-dimethylphenoxy)propan-2-amine
(2Rs)-1-(2,6-Dimethylphenoxy)-2-aminopropane
(2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane
1-(2',6'-dimethylphenoxy)-2-aminopropane
1-(2',6'-Dimethylphenoxy)-2-aminopropane
1-(2,6-dimethylphenoxy)-2-propanamine
1-(2,6-Dimethylphenoxy)-2-propanamine
1-(2,6-dimethylphenoxy)propan-2-amine
1-methyl-2-(2,6-xylyloxy)ethanamine
1-Methyl-2-(2,6-xylyloxy)ethanamine
1-Methyl-2-(2,6-xylyloxy)ethylamine
2-(2-aminopropoxy)-1,3-dimethylbenzene
2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride
31828-71-4
5370-01-4 (hydrochloride)
AB00053683
AC1L1HL7
AC1Q2BC5
AC1Q2BC6
Boehringer ingelheim brand OF mexiletine hydrochloride
BPBio1_000026
BRD-A64092382-003-04-3
BRN 2092205
BSPBio_000022
BSPBio_002254
C07220
CHEBI:115958
CHEBI:6916
CHEMBL558
CID4178
D08215
DB00379
DivK1c_000834
EINECS 250-825-7
I01-6374
IDI1_000834
KBio1_000834
KBio2_002082
KBio2_004650
KBio2_007218
|
KBio3_001474
KBioGR_001270
KBioSS_002082
KO1173
KO-1173
KOE-1173
Lopac0_000784
LS-68257
Mexiletene
Mexiletina
Mexiletina [INN-Spanish]
Mexiletine
Mexilétine
Mexiletine (INN)
Mexiletine [INN:BAN]
Mexiletine HCL
Mexiletine hydrochloride
Mexiletinum
Mexiletinum [INN-Latin]
Mexilitine
Mexitil
Mexitil PL
Mexityl
MolPort-001-790-944
NCGC00015659-04
NCGC00162253-01
NCGC00162253-02
NINDS_000834
novo Mexiletine
novo-Mexiletine
Novopharm brand OF mexiletine hydrochloride
Prestwick0_000241
Prestwick1_000241
Prestwick2_000241
Prestwick3_000241
SBB070242
SPBio_002241
Spectrum_001602
Spectrum3_000727
Spectrum4_000795
Spectrum5_001279
UNII-1U511HHV4Z
|
|
20 |
|
Mecasermin |
Approved, Investigational |
Phase 1, Phase 2 |
|
68562-41-4 |
|
Synonyms:
Human somatomedin C
Mecasermin recombinant
|
Mecasermina
Mechano growth factor
|
|
21 |
|
Clarithromycin |
Approved |
Phase 2 |
|
81103-11-9 |
84029 |
Synonyms:
(14R)-14-Hydroxyclarithromycin
116836-41-0
6-O-methyl erythromycin
6-O-methylerythromycin
6-O-Methylerythromycin
6-O-methylerythromycin A
6-O-Methylerythromycin a
81103-11-9
A-56268
Abbotic
Abbott-56268
AC1L1HJO
AC1L36NJ
AC1NFSZE
AC1NR4MY
AC1NSJWH
AC1O52DV
AC1Q6O1T
AC-6813
Adel
ANX-015
Astromen
BB_NC-1450
Biaxin
Biaxin (TN)
Biaxin filmtab
Biaxin HP
Biaxin XL
Biaxin xl filmtab
Bicrolid
BIDD:GT0200
Bio-0020
BSPBio_003453
C06912
C2220
C30H54O11.C9H19NO2
CCRIS 8833
CHEBI:136451
CHEBI:3732
CHEMBL143
CHEMBL1741
CID10147055
CID10328822
CID11814635
CID11828745
CID11969952
CID4663848
CID489010
CID5284534
CID5311050
CID54688
CID6426662
CID84029
CID9810688
CID9811194
CLA
Clacine
Clambiotic
Claribid
Claricide
Clarith
clarithromycin
Clarithromycin
Clarithromycin & Interleukin-12
Clarithromycin (JP15/USP/INN)
Clarithromycin [USAN:INN:BAN:JAN]
Clarithromycin extended release
Clarithromycin suspension or tablets
clarithromycina
Clarithromycina
Clarithromycine
Clarithromycine [INN-French]
Clarithromycinum
Clarithromycinum [INN-Latin]
|
Claritromicina
Claritromicina [INN-Spanish]
Clathromycin
CLM & IL-12
CPD000466382
CRL-1605 & Clarithromycin
CTY
Cyllid
Cyllind
D00276
DivK1c_006655
DRG-0099
Helas
Heliclar
HMS1922H09
HMS2051G18
HMS2090O11
HMS2094M05
hydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexame
I05-0074
KBio1_001599
KBio2_000509
KBio2_003077
KBio2_005645
KBio3_002673
KBioGR_001218
KBioSS_000509
Klacid
Klaciped
Klaricid
Klaricid H.P
Klaricid H.P.
Klaricid Pediatric
Klaricid XL
Klarid
Klarin
Klax
Kofron
Lactoferrin B & Clarithromycin
Lactoferrin H & Clarithromycin
LMPK04000014
LS-1812
Mabicrol
Macladin
Maclar
Mavid
MLS000759516
MLS001201751
MLS001424066
MolPort-002-507-425
MolPort-003-845-969
MolPort-005-910-192
MolPort-005-934-146
Naxy
NCGC00178054-01
NSC643733
O(6)-methylerythromycin
SAM001246748
SDP-015
SMR000466382
SPBio_001855
SpecPlus_000559
Spectrum_000089
SPECTRUM1504231
Spectrum2_001668
Spectrum3_001667
Spectrum4_000629
Spectrum5_001729
STK801952
TE031
TE-031
UNII-H1250JIK0A
Veclam
Zeclar
|
|
22 |
|
Anti-Arrhythmia Agents |
|
Phase 2 |
|
|
|
23 |
|
Insulin, Globin Zinc |
|
Phase 1, Phase 2 |
|
|
|
24 |
|
Mitogens |
|
Phase 1, Phase 2 |
|
|
|
25 |
|
insulin |
|
Phase 1, Phase 2 |
|
|
|
26 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 2 |
|
|
|
27 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
28 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
29 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
30 |
|
Cytochrome P-450 CYP3A Inhibitors |
|
Phase 2 |
|
|
|
31 |
|
Ranolazine |
Approved, Investigational |
Phase 1 |
|
142387-99-3, 95635-55-5 |
56959 |
Synonyms:
( -)-Ranolazine
(-)-Ranolazine
142387-99-3
95635-55-5
AC-1673
AC1L1M17
AC1Q5LYD
BRD-A97674275-001-01-9
BSPBio_002276
CHEMBL1404
CID56959
CVT-303
D05700
DB00243
Dihydrochloride, ranolazine
HCL, Ranolazine
HMS1922F16
HMS2090L09
HMS2093D21
Hydrochloride, ranolazine
I01-2008
I06-0160
KEG-1295
Latixa
Lopac0_001062
LS-187267
MLS002154149
MolPort-003-666-653
N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
|
N-(2,6-Dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide
NCGC00015897-05
NCGC00095177-01
NCGC00095177-02
NCGC00095177-03
RAN D
Ran4
Ranexa
Ranexa (TN)
Ranexa, Ranolazine
Ranolazina
ranolazine
Ranolazine
RANOLAZINE
Ranolazine (USAN/INN)
Ranolazine 2HCl
Ranolazine 2HCL
Ranolazine dihydrochloride
Ranolazine Dihydrochloride
Ranolazine HCL
Ranolazine hydrochloride
Renolazine
RS-43285
RS-43285-003
S1799_Selleck
SMR000857382
SPECTRUM1505366
UNII-A6IEZ5M406
|
|
32 |
|
Modafinil |
Approved, Investigational |
|
|
68693-11-8 |
4236 |
Synonyms:
2-((diphenylmethyl)sulfinyl)acetamide
2-((Diphenylmethyl)sulfinyl)acetamide
Alertec
Benzhydrylsulfinylacetamide
CEPA brand OF modafinil
Cephalon brand OF modafinil
Cephalon brand OF modafinil, reformulated
Dea No. 1680
Draxis brand OF modafinil
Lafon brand OF modafinil
Merckle brand OF modafinil
modafinil
|
Modafinil
Modafinil [Usan:Inn]
Modafinilo
Modafinilo [Spanish]
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Nourypharma brand OF modafinil
Provigil
Sparlon
Vigil
|
|
33 |
|
Fibrinolysin |
Investigational |
|
|
9004-09-5 |
|
Synonyms:
Bovine Fibrinolysin
Bovine Plasmin
Fibrinolysin (human)
Fibrinolysin, human
|
Plasmin (bos taurus)
Plasmin (bovine)
Plasmin bovine
|
|
34 |
|
Hemostatics |
|
|
|
|
|
35 |
|
Antifibrinolytic Agents |
|
|
|
|
|
36 |
|
Lupus Coagulation Inhibitor |
|
|
|
|
|
37 |
|
Anticoagulants |
|
|
|
|
|
38 |
|
Liver Extracts |
|
|
|
|
|
39 |
|
Plasminogen |
|
|
|
|
|
40 |
|
Coagulants |
|
|
|
|
|
41 |
|
Cola |
|
|
|
|
|
42 |
|
Central Nervous System Stimulants |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 58)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Evaluation of Arrhythmic Risk in Myotonic Dystrophy Type I (DM 1) |
Unknown status |
NCT00127582 |
Phase 3 |
|
2 |
Study of Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Ventilation in Adults With Myotonic Dystrophy Type 1(DM1) |
Unknown status |
NCT01225614 |
Phase 3 |
|
3 |
Phase 2/3 Study of Efficacy and Tolerability of Methylphenidate in the Treatment of Excessive Daytime Sleepiness in Myotonic Dystrophy Type 1 |
Completed |
NCT01421992 |
Phase 2, Phase 3 |
Methylphenidate;Placebo |
4 |
Lamotrigine as Treatment of Myotonia - a Phase 3 Randomized Controlled Trial Study |
Completed |
NCT01939561 |
Phase 3 |
Lamotrigine;Placebo |
5 |
Phase 3 Study of Oral Dehydroepiandrosterone (DHEA) in Adults With Myotonic Dystrophy |
Completed |
NCT00167609 |
Phase 2, Phase 3 |
dehydroepiandrosterone 100 and 400 mg |
6 |
A Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Tideglusib Versus Placebo for the Treatment of Children and Adolescents With Congenital Myotonic Dystrophy |
Not yet recruiting |
NCT03692312 |
Phase 2, Phase 3 |
Tideglusib;Placebo |
7 |
A Placebo Controlled, Randomized, Double-Blind Phase II Clinical Trial to Evaluate Tolerability, Safety and Efficacy Endpoints After Administration of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) for 24 Weeks in Adults With Myotonic Dystrophy Type 1 |
Unknown status |
NCT00577577 |
Phase 2 |
rhIGF-I/rhIGFBP-3;placebo |
8 |
A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy |
Completed |
NCT02858908 |
Phase 2 |
Tideglusib |
9 |
A Randomized, Placebo Controlled, Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type-1 (DM1) |
Completed |
NCT01406873 |
Phase 2 |
Mexiletine;Placebo |
10 |
A Phase 1/2a Blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, and Dose-range Finding of Multiple Ascending Doses of ISIS 598769 Administered Subcutaneously to Adult Patients With Myotonic Dystrophy Type 1 |
Completed |
NCT02312011 |
Phase 1, Phase 2 |
IONIS-DMPKRx;Placebo |
11 |
Effects of SomatoKine (Iplex) (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) |
Completed |
NCT00233519 |
Phase 1, Phase 2 |
SomatoKine/IPLEX |
12 |
Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes |
Recruiting |
NCT04026958 |
Phase 2 |
Clarithromycin;Placebo |
13 |
Intramuscular Transplantation of Autologous Muscle Derived Stem Cell(MDSC) and Adipose Derived Mesenchymal Stem Cells (AD-MSC) in Patients With Facioscapulohumeral Dystrophy (FSHD), Phase I Clinical Trial |
Unknown status |
NCT02208713 |
Phase 1 |
|
14 |
Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation to Manage or Treat Muscular Dystrophies. |
Unknown status |
NCT00674843 |
Phase 1 |
|
15 |
Open Label Trial of Ranolazine in Myotonia Congenita, Paramyotonia Congenita, & Myotonic Dystrophy Type 1 |
Completed |
NCT02251457 |
Phase 1 |
Ranolazine |
16 |
Double-Blind, Placebo-Controlled, Dose-Range-Finding, Crossover Trial of Single Day Administration of ERX-963 in Adults With Myotonic Dystrophy Type 1 |
Completed |
NCT03959189 |
Phase 1 |
ERX-963;Placebo |
17 |
Function, Structure and Quality of Striated Muscles in Patients With Muscular Diseases - an MRI Study on Pompe Disease and Dystrophia Myotonica |
Unknown status |
NCT02708784 |
|
|
18 |
Defining and Managing the Neuropsychological Abnormalities of Myotonic Dystrophy |
Unknown status |
NCT02269865 |
|
|
19 |
Myotonic Dystrophy Type 1 (DM1) Deep Phenotyping to Improve Delivery of Personalized Medicine and Assist in the Planning, Design and Recruitment of Clinical Trials |
Unknown status |
NCT02831504 |
|
|
20 |
Four Weeks Withdrawal of Non-invasive Ventilation (NIV) in Patients With Myotonic Dystrophy: Cardiovascular, Metabolic and Daytime Vigilance Induced Changes |
Unknown status |
NCT00745238 |
|
|
21 |
Non Invasive Prenatal Diagnosis on Isolated Circulating Fetal Trophoblastic Cells (CFTC) for Triplet Repeat Diseases |
Unknown status |
NCT03087526 |
|
|
22 |
Validation of a German Language Screening Questionnaire for Symptoms of Respiratory Muscle Weakness and Sleep-disordered Breathing in Patients With Neuromuscular Disorders |
Unknown status |
NCT02833168 |
|
|
23 |
NON-INVASIVE PRENATAL TESTING (NIPT) OF FETAL SINGLE-GENE DISORDERS IN MATERNAL BLOOD |
Unknown status |
NCT02339402 |
|
|
24 |
Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1 |
Completed |
NCT04018820 |
|
|
25 |
Effects of a Multiple Component Training Program on Muscles, Maximal Muscle Strength, Endurance and Functional Performance in Adults With Myotonic Dystrophy Type 1: A Pilot Study |
Completed |
NCT04001920 |
|
|
26 |
Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study |
Completed |
NCT02729597 |
|
|
27 |
Cardiac and Respiratory Prognostic Factors in Patients With Myotonic Dystrophy Type 1 |
Completed |
NCT01136330 |
|
|
28 |
Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ? |
Completed |
NCT02375087 |
|
|
29 |
A Multicenter Observational Study to Assess the Variability of Molecular Biomarkers and Clinical Measures in Patients With Myotonic Dystrophy Type 1 |
Completed |
NCT02308657 |
|
|
30 |
Prospective Randomized Controlled Single Blind Study of Efficacy and Tolerance of AVAPS Mode Compared to Bilevel Pressure Ventilation un Adult Patients With Myotonic Dystrophy |
Completed |
NCT01530841 |
|
|
31 |
Incidence and Predictors of Venous Thromboembolism in Myotonic Dystrophy |
Completed |
NCT03141749 |
|
|
32 |
Observational Trial in Myotonic Dystrophy Type 2 to Define Specific Clinical Outcome Measures |
Completed |
NCT03603171 |
|
|
33 |
Brain Involvement in Myotonic Dystrophy Type I: From Functional Neuroimaging to the Impact on Quality of Life |
Completed |
NCT03589677 |
|
|
34 |
Myotonic Dystrophy:Muscle Wasting and Altered Metabolism |
Completed |
NCT00004769 |
|
|
35 |
Lung Function Impairment and Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients |
Completed |
NCT01242007 |
|
|
36 |
A Registry of Arrhythmias in Myotonic Muscular Dystrophy |
Completed |
NCT00622453 |
|
|
37 |
Observational Prolonged Trial in Myotonic Dystrophy Type 1 to Improve Quality of Life Standards, a Target Identification Collaboration |
Completed |
NCT02118779 |
|
|
38 |
Pulmonary Hypertension--Mechanisms and Family Registry |
Completed |
NCT00005357 |
|
|
39 |
The UK National Registry for Myotonic Dystrophy |
Recruiting |
NCT04003363 |
|
|
40 |
Effect of Noninvasive Mechanical Ventilation on Ventilatory Response in Patients With Myotonic Dystrophy Type 1 |
Recruiting |
NCT02880735 |
|
|
41 |
The Electrophysiological Study Guided ICD Strategy in Prevention of Arrhythmic Cardiac Death in Myotonic Dystrophy Type 1 Patients With Conduction System Disease (ACADEMY 1 Study) |
Recruiting |
NCT03784586 |
|
|
42 |
Venous Thromboembolism in Myotonic Dystrophy Type 1 |
Recruiting |
NCT03424460 |
|
|
43 |
Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years |
Recruiting |
NCT03764150 |
|
|
44 |
Myotonic Dystrophy Family Registry |
Recruiting |
NCT02398786 |
|
|
45 |
National Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Patients and Family Members |
Recruiting |
NCT00082108 |
|
|
46 |
Assessing Clinical Endpoint and Biomarkers in Myotonic Dystrophy Type-1 and Type-2 |
Recruiting |
NCT03867435 |
|
|
47 |
A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives |
Recruiting |
NCT01931644 |
|
|
48 |
Functional and Cellular Benefits of Aerobic Exercise in Myotonic Dystrophy Type 1 Patients |
Active, not recruiting |
NCT04187482 |
|
|
49 |
DM-IMT - Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1 |
Enrolling by invitation |
NCT04052958 |
|
|
50 |
Muscle Relaxation Properties in Myopathies With Positive Muscle Phenomena: a Study Using Transcranial Magnetic Stimulation |
Enrolling by invitation |
NCT03211923 |
|
|
|